SCHEMBL419648

SCHEMBL419648

CC1(C)OB(c2ccc(Cl)c(Cl)c2)OC1(C)C

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LPL P06858 13/20 0.48
LIPG Q9Y5X9 13/20 0.48
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
EGFR P00533 2/20 0.40
F11 P03951 1/20 0.40
AAK1 Q2M2I8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4425474 0.86 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL30622816 0.86 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL57994 0.85 LPL (0.46) LPLLIPGCA1CA2CA9
SCHEMBL16688104 0.85 LPL (0.46) LPLLIPGCA1CA2CA9
Ammonia Solution, Strong SCHEMBL28537357 0.85 LPL (0.46) LPLLIPGCA1CA2CA9
SCHEMBL4426022 0.85 LPL (0.46) LPLLIPGCA1CA2CA9
SCHEMBL24524492 0.83 LPL (0.44) LPLLIPGCA1CA2CA9
SCHEMBL177624 0.83 LPL (0.44) LPLLIPGCA1CA2CA9
SCHEMBL1437613 0.83 EGFR (0.55) LPLLIPGCA1CA2CA9
SCHEMBL31342073 0.83 LPL (0.51) LPLLIPGCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090589-A1 HETEROCYCLIC HBS1L DEGRADERS TANGO THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
US-20230331654-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING SAME, AND ELECTRONIC DEVICE THEREOF DUK SAN NEOLUX CO., LTD. (KR) 2023-10-19 US disclosed
US-20230331654-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING SAME, AND ELECTRONIC DEVICE THEREOF DUK SAN NEOLUX CO., LTD. (KR) 2023-10-19 US disclosed
US-10647733-B2 Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations THE UNIVERSITY OF CHICAGO (US) 2020-05-12 US disclosed
US-20170182486-A1 METAL-ORGANIC FRAMEWORKS CONTAINING NITROGEN-DONOR LIGANDS FOR EFFICIENT CATALYTIC ORGANIC TRANSFORMATIONS THE UNIVERSITY OF CHICAGO (US) 2017-06-29 US disclosed
US-20150191493-A1 NEW PROCESS FOR PREPARING ARYLBORANES BY ARYLATION OF ORGANOBORON COMPOUNDS Universite de Bordeaux (FR) 2015-07-09 US disclosed
US-20150191493-A1 NEW PROCESS FOR PREPARING ARYLBORANES BY ARYLATION OF ORGANOBORON COMPOUNDS Universite de Bordeaux (FR) 2015-07-09 US disclosed
US-20150191493-A1 NEW PROCESS FOR PREPARING ARYLBORANES BY ARYLATION OF ORGANOBORON COMPOUNDS Universite de Bordeaux (FR) 2015-07-09 US disclosed
EP-2684887-B1 New process for preparing arylboranes by arylation of organoboron compounds UNIV BORDEAUX (FR) 2015-06-17 EP disclosed
EP-2872519-A1 NEW PROCESS FOR PREPARING ARYLBORANES BY ARYLATION OF ORGANOBORON COMPOUNDS UNIVERSITE DE BORDEAUX (FR) 2015-05-20 EP disclosed
US-8404670-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2013-03-26 US disclosed
EP-2481742-A1 PREPARATION METHOD OF AROMATIC BORATE ESTER COMPOUND Peking University (CN) 2012-08-01 EP disclosed
EP-2481742-A1 PREPARATION METHOD OF AROMATIC BORATE ESTER COMPOUND Peking University (CN) 2012-08-01 EP disclosed
US-20120184768-A1 PREPARATION METHOD OF AROMATIC BORONATE COMPOUNDS PEKING UNIVERSITY (CN) 2012-07-19 US disclosed
US-20120184768-A1 PREPARATION METHOD OF AROMATIC BORONATE COMPOUNDS PEKING UNIVERSITY (CN) 2012-07-19 US disclosed
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2012-01-26 US disclosed
EP-2396327-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2011-12-21 EP disclosed
US-8063032-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-11-22 US disclosed
WO-2010093425-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2010-08-19 WO disclosed
US-20100204214-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331654-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING SAME, AND ELECTRONIC DEVICE THEREOF OCIAD1, OCIAD2, ORAI2 LPL 601/4885LIPG 380/4885CA1 3213/4885
US-10647733-B2 Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations NCLN, MDH1, NNMT LPL 4013/4885LIPG 3849/4885CA1 1109/4885
US-20170182486-A1 METAL-ORGANIC FRAMEWORKS CONTAINING NITROGEN-DONOR LIGANDS FOR EFFICIENT CATALYTIC ORGANIC TRANSFORMATIONS NCLN, MDH1, NNMT LPL 4013/4885LIPG 3849/4885CA1 1109/4885
US-20120184768-A1 PREPARATION METHOD OF AROMATIC BORONATE COMPOUNDS AHR, BLVRB, AR LPL 4008/4885LIPG 3859/4885CA1 4497/4885
US-20100204214-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 LPL 3488/4885LIPG 3575/4885CA1 1722/4885
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 LPL 3488/4885LIPG 3575/4885CA1 1722/4885
US-20150191493-A1 NEW PROCESS FOR PREPARING ARYLBORANES BY ARYLATION OF ORGANOBORON COMPOUNDS NISCH, BRD7, BRSK2 LPL 4543/4885LIPG 4066/4885CA1 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.